Insider Selling: Michael A. Mussallem Unloads 29,500 Shares of Edwards Lifesciences Corp Stock (EW)
Edwards Lifesciences Corp (NYSE:EW) CEO Michael A. Mussallem sold 29,500 shares of Edwards Lifesciences Corp stock on the open market in a transaction dated Thursday, July 31st. The shares were sold at an average price of $91.98, for a total value of $2,713,410.00. Following the completion of the transaction, the chief executive officer now directly owns 263,850 shares in the company, valued at approximately $24,268,923. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
A number of analysts have recently weighed in on EW shares. Analysts at Stifel Nicolaus raised their price target on shares of Edwards Lifesciences Corp from $90.00 to $100.00 in a research note on Thursday. Separately, analysts at JPMorgan Chase & Co. raised their price target on shares of Edwards Lifesciences Corp from $78.00 to $90.00 in a research note on Thursday. Finally, analysts at CRT Capital raised their price target on shares of Edwards Lifesciences Corp from $90.00 to $100.00 in a research note on Thursday. Six equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Edwards Lifesciences Corp presently has an average rating of “Buy” and a consensus target price of $90.00.
Edwards Lifesciences Corp (NYSE:EW) traded up 1.91% on Friday, hitting $91.97. 1,899,876 shares of the company’s stock traded hands. Edwards Lifesciences Corp has a 1-year low of $60.62 and a 1-year high of $94.50. The stock has a 50-day moving average of $85.98 and a 200-day moving average of $77.78. The company has a market cap of $9.712 billion and a P/E ratio of 13.02.
Edwards Lifesciences Corp (NYSE:EW) last announced its earnings results on Tuesday, July 29th. The company reported $0.88 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.77 by $0.11. The company had revenue of $547.00 million for the quarter, compared to the consensus estimate of $545.10 million. During the same quarter last year, the company posted $0.82 earnings per share. Edwards Lifesciences Corp’s revenue was up 11.2% compared to the same quarter last year. On average, analysts predict that Edwards Lifesciences Corp will post $3.28 earnings per share for the current fiscal year.
Edwards Lifesciences Corporation (NYSE:EW) is focused on technologies that treat structural heart disease and critically ill patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.